Author: sugaradmin

Introduction and Objective: GLP-1RAs and SGLT2is reduce cardiometabolic risk in patients with T2D, but high OOP costs limit access among lower-income Medicare Part D enrollees not receiving subsidies (income >150% federal poverty level [FPL]). It is unclear which income levels are most vulnerable to cost-related medication discontinuation. Evidence is needed to inform equitable policy design […]

Introduction and Objective: The FreeDM2 randomized controlled trial (NCT05944432) demonstrated that real-time continuous glucose monitoring (CGM) with FreeStyle Libre 3 led to a significant improvement in A1c at 16 weeks, compared to self-monitoring of blood glucose (SMBG). This analysis assessed whether benefits are consistent across type 2 diabetes (T2DM) characteristics.Methods: The primary outcome, mean change […]

Introduction and Objective: CGM can improve glucose levels for insulin-treated type 2 diabetes (T2D). Small trials have found benefits of CGM for T2D not on insulin therapy (NIT), but a fully powered RCT is needed to provide higher-level evidence for this population. To meet this need, we are conducting a multicenter RCT of CGM use […]

Introduction and Objective: SARS-CoV-2 infection is associated with increased risk of diabetes mellitus (DM). Paxlovid (nirmatrelvir/ritonavir) is an antiviral approved for individuals at high risk for severe SARS-CoV-2 infection, but its effect on post-SARS-CoV-2 DM risk is unknown. We examined whether outpatient Paxlovid use was associated with incident DM over 2 years in adults aged […]

Introduction and Objective: This study aimed to develop and validate a novel dual-endpoint model to simultaneously predict 10-year risks of type 2 diabetes (T2D) and cardiovascular disease (CVD) in individuals with prediabetes, enabling more comprehensive risk stratification.Methods: We included 18,848 participants with prediabetes from the Kailuan cohort for model derivation and internal validation, and 46,828 […]

Introduction and Objective: Evidence of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in type 1 diabetes (T1D) is limited to short-term trials with surrogate endpoints. Using real-world data, we aimed to assess long-term clinical outcomes of SGLT2i in T1D.Methods: Using electronic health record data from Optum Labs Data Warehouse, we conducted monthly sequential target trial emulation (SGLT2i initiation […]

Introduction and Objective: Diabetic foot ulcers complicated by lower limb ischemia are common complications in the person with diabetes, leading to non-traumatic amputations. Currently, there are no specific drugs, and treatment is limited to surgical intervention. This study explores the therapeutic effects and mechanisms of multi-cell fusion-based 3D-printed bioengineered skin, incorporating engineered exosomes, for treating […]

Introduction and Objective: Detecting dysglycemia at early stages of T1D can prevent DKA and improve long-term outcomes. OGTT, currently recommended for monitoring progression, can be challenging in clinical care. HbA1c is not sufficiently sensitive, particularly in young children. We aimed to identify CGM metrics predicting progression to stage 3 T1D.Methods: 171 participants prospectively followed in […]

Introduction and Objective: Maternal obesity is increasingly recognized as a determinant of long-term metabolic risk in offspring, yet the cellular mechanisms by which maternal nutritional status primes adipose tissue for coordinated remodeling across generations remain poorly defined. Traditional research has focused on metabolic dysfunction, failing to explain why certain maternal-offspring dietary combinations produce distinct phenotypic […]